Last reviewed · How we verify
control group C
The mechanism of action for the control group C is not specified.
At a glance
| Generic name | control group C |
|---|---|
| Sponsor | Kasr El Aini Hospital |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As the control group C does not have a defined active ingredient, its mechanism of action cannot be described. It may serve as a placebo or comparator in clinical trials.
Approved indications
Common side effects
Key clinical trials
- GCF and Saliva Levels of IL-36α in Periodontal Disease (NA)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Toddler Biomarker of Nutrition Study (NA)
- A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma (PHASE2, PHASE3)
- Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1 (PHASE3)
- Adding Mini-squat Exercises to Leg Press Exercise on Quadriceps and Hamstring Strength and H:Q Ratio in Athletes (NA)
- Asymmetric High-Flow Nasal Cannula During Pulmonary Rehabilitation in COPD (NA)
- Effects of Intensive Virtual Reality-Based Balance and Gait Training on Activity Performance and Quality of Life in Subacute Stroke Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |